about
MicroRNAs in Valvular Heart Diseases: Potential Role as Markers and Actors of Valvular and Cardiac RemodelingClinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research ConsortiumValve Stress Echocardiography: A Practical Guide for Referral, Procedure, Reporting, and Clinical Implementation of Results From the HAVEC GroupPulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC GroupQuantitative analysis of semi-supine exercise echocardiography--influence of age on myocardial Doppler imaging indicesIntracardiac flow visualization: current status and future directionsEchocardiographic integrated backscatter for detecting progression and regression of aortic valve calcifications in rats.Use of contrast echocardiography in intensive care and at the emergency room.Comparison of contrast enhanced three dimensional echocardiography with MIBI gated SPECT for the evaluation of left ventricular function.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociThe use of pocket-size imaging devices: a position statement of the European Association of Echocardiography.European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease).Serum albumin level and hospital mortality in acute non-ischemic heart failure.2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Elevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis.Centres of excellence in heart valve surgery: are there standards for best practice?New biomarkers for primary mitral regurgitation.Stress testing in valve diseaseYoung community of EACVI: the transition from EACVI Club 35 to Heart Imagers of Tomorrow: a promising yet challenging step.Impact of contractile reserve on acute response to cardiac resynchronization therapy.European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies.The value of 2D strain imaging during stress testing.A statement on ethics from the HEART Group.Safety of ultrasound contrast agents: "Primum non nocere"?Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?Ischaemic mitral regurgitation: mechanisms and diagnosis.Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects.Exercise echocardiography in asymptomatic patients with severe aortic stenosis and preserved left ventricular ejection fraction.Stress echocardiography for selecting potential responders to cardiac resynchronisation therapy.Exercise echocardiography in severe asymptomatic aortic stenosis.Stress Doppler echocardiography in valvular heart diseases: utility and assessment.Management of multiple valve disease.Stress testing in valvular heart disease: clinical benefit of echocardiographic imaging.Left atrial function: pathophysiology, echocardiographic assessment, and clinical applications.Ischemic mitral regurgitation: not only a bystander.Drug-induced valvular heart disease.Republished: drug-induced valvular heart disease.
P50
Q26740102-20BE1924-5F31-484E-8A09-764D3D4AC013Q26799831-71E401BD-C26E-44FE-B6E7-E2AD2F558511Q27015479-8BB8B728-693F-4F83-9113-5C459C390D02Q28083081-62795675-94C1-41A7-B0D8-2F330806EC4EQ28254200-12B5714C-FAB7-4C26-AF4F-64C23848DD22Q30427024-A4C75D7F-5198-4295-B13F-149BDA87D38CQ30456255-C8C57A9F-0007-4046-B64E-4DFADDD8E003Q30465086-F6ED2A78-D205-4120-9932-07125C384F69Q30488745-6A85AC75-2389-480B-8F9E-15B0D0DEB138Q33162947-B6281DD7-9FE4-4F41-B372-63708FB02858Q33438526-37114AAB-E9F2-4677-9ED3-2919F1687344Q33550673-821F999B-13D9-47EC-BB19-CCC282A60515Q33577460-EB2B3BE5-D566-4526-B3CD-8F8758642B81Q34351265-AD1AF222-254C-434E-A047-BDB43E8BCAFAQ34368081-7DF044D2-EC39-4CBF-AB21-7B2B556C8B4FQ34491521-DB5A31EA-054B-4963-9F99-186EC4F9BD9DQ34491530-C79A73AC-551C-44B7-8632-CDFBB9E704BFQ35782067-0F18E171-96C5-4F4E-83AF-4D941A62BA23Q35844082-F0FF848A-A7F1-41D7-A4AD-C03BE10333CAQ36088357-A6CC44BD-E2EF-43C0-A01D-FC402E8327C0Q36821856-34A62F97-5AFD-4431-9676-FEA066334B22Q36942213-61106F9E-C8F9-4728-B5AB-5D182A01C97FQ37042258-2AF4C7C6-F697-42E6-8D91-2A565D2C5F37Q37200104-12F773D9-66BD-4264-80AF-017CC64C801AQ37416296-F9374A33-52FD-4DB8-95CD-E43494D59AD8Q37438759-034ACEB9-09A2-4A8F-9338-F193DF564CF4Q37590830-CED9958D-63FC-4351-890C-AF4BB7C36D02Q37591706-9BC68E23-2B10-4380-8401-EA9223495DDCQ37604711-747CE002-E402-4214-A337-F8AC5D9573D0Q37611300-DA762610-FF3A-45C5-AA5A-396A9B4667F9Q37711346-44D53DED-81F3-43D1-85EB-29DAEB56E7D7Q37770808-BD2E7A61-C368-4D27-88F3-4C9D5990730AQ37775404-D236AB71-6371-4028-B2A3-90A1C5053094Q37798808-B0FA47E4-3925-4037-BD43-BF363EC2CC74Q37820779-B9D80C75-BE98-4CAE-A153-7208A859FD05Q37821914-E9EC6489-D5AF-4A6C-9414-A6E84042BAF9Q37953350-0B1C8A1E-BAFE-4BEE-8F4A-D02DDE3624B9Q37971865-2C47BB88-4ED3-4AED-B2A4-5E480A1AE093Q38033130-3B6421EA-5EEF-4950-AE80-2444E8C5E4D4Q38082453-F5995785-637B-48E2-8B7E-F9511ADAD5E0
P50
name
Patrizio Lancellotti
@ast
Patrizio Lancellotti
@en
Patrizio Lancellotti
@es
Patrizio Lancellotti
@nl
type
label
Patrizio Lancellotti
@ast
Patrizio Lancellotti
@en
Patrizio Lancellotti
@es
Patrizio Lancellotti
@nl
prefLabel
Patrizio Lancellotti
@ast
Patrizio Lancellotti
@en
Patrizio Lancellotti
@es
Patrizio Lancellotti
@nl
P21
P214
108148997579859870000
P31
P735
P7859
lccn-nb2015002759